Compare AbbVie Inc (ABBV) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Avantis US Small Cap Value ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Avantis US Small Cap Value ETF trades at $122.5. The key difference: AbbVie Inc pays a 2.72% dividend while Avantis US Small Cap Value ETF pays none. Which is the better fit depends on your goals.
| ABBV | AVUV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $124.94 |
52-Week Low | $184.85 | $90.37 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
AVUV trades at $123.82, up 0.25% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF's small-cap value focus has gained attention amid a market rotation, with recent news highlighting its outperformance versus growth peers and potential benefits from shifting rate expectations. Support and resistance levels are closely watched near current prices.
The outlook for AVUV hinges on continued small-cap value strength, though exposure to regional banks and sensitivity to interest rates pose risks. Its active management approach aims to capture the value premium, but elevated volatility relative to large-caps remains a consideration for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
